Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)

China · Delayed Price · Currency is CNY

8.44

-0.06 (-0.71%)

Jul 30, 2026, 3:04 PM CST

SHE:002693 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Revenue	288.53	276.76	174.21	235.93	274.75	320.29
Revenue Growth	71.62%	58.87%	-26.16%	-14.13%	-14.22%	18.87%
Gross Profit	156.23	144.2	89.83	153.52	180.1	232.61
Operating Income	32.01	17.35	-71.77	-36.83	-44.24	-49.62
Net Income	32.53	19.04	-78.3	-50.74	9.01	-20.33
Earnings Per Share	0.09	0.05	-0.19	-0.12	0.02	-0.05
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Self-Produced Medicine Sales Business	247.24
Entrusted Business	92
Other Business	5.78
Inter-Segment Elimination	-68.26
Total	276.76

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Investments	74.14	59.1	45.11	31.9	146.01	77.02
Total Debt	294.43	280.73	276.21	186.05	223.36	177.7
Net Cash (Debt)	-220.29	-221.64	-231.1	-154.15	-77.35	-100.67
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.58	-0.58	-0.56	-0.36	-0.17	-0.25

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Cash Flow	85.98	60.95	-40.83	11.64	25.22	23.55
Capital Expenditures	-46.72	-43.27	-24.91	-49.2	-32.98	-31.64
Free Cash Flow	39.26	17.68	-65.73	-37.56	-7.77	-8.09
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Gross Margin	54.15%	52.10%	51.56%	65.07%	65.55%	72.62%
Operating Margin	11.09%	6.27%	-41.20%	-15.61%	-16.10%	-15.49%
Pretax Margin	7.30%	2.95%	-60.95%	-30.93%	-3.23%	-12.60%
Profit Margin	11.28%	6.88%	-44.95%	-21.51%	3.28%	-6.35%
FCF Margin	13.61%	6.39%	-37.73%	-15.92%	-2.83%	-2.52%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
PE Ratio	99.55	151.56	-	-	334.55	-
Forward PE	-	18.69	18.69	18.69	18.69	18.69
P/FCF Ratio	89.77	163.27	-	-	-	-
PS Ratio	12.22	10.43	43.63	13.26	10.97	6.07